Neurogene Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Neurogene Inc. (NGNE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $100.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-20.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2023-11-14
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-12-31 was $0.00.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-03-31 was $100.00K, a 90.00% decline year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $100.00K, a 92.31% decline from fiscal 2021.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $1.30M, a 78.33% decline from fiscal 2020.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $6.00M, a 361.54% increase from fiscal 2019.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2019 was $1.30M, a 333.33% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 derived: sum of 3 quarters · filed 2023-11-14 | $100.00K 10-K · filed 2023-03-20 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $100.00K 10-Q · filed 2023-11-14 | $100.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $100.00K 10-Q · filed 2023-08-10 | $100.00K derived: sum of 3 quarters · filed 2023-08-10 | $200.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-08 | $100.00K derived: sum of 2 quarters · filed 2023-05-08 | $200.00K derived: sum of 3 quarters · filed 2023-05-08 | $400.00K derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $100.00K derived: sum of 2 quarters · filed 2023-03-20 | $300.00K derived: sum of 3 quarters · filed 2023-03-20 | $1.30M 10-K · filed 2023-03-20 |
| 2021-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $300.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.30M 10-Q · filed 2022-11-14 | $4.50M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.20M 10-Q · filed 2022-08-09 | $4.40M derived: sum of 3 quarters · filed 2022-08-09 | $4.80M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $1.00M 10-Q · filed 2022-05-09 | $4.20M derived: sum of 2 quarters · filed 2022-05-09 | $4.60M derived: sum of 3 quarters · filed 2022-05-09 | $5.70M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $3.60M derived: sum of 2 quarters · filed 2022-03-01 | $4.70M derived: sum of 3 quarters · filed 2022-03-01 | $6.00M 10-K · filed 2022-03-01 |
| 2020-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.50M derived: sum of 2 quarters · filed 2021-11-04 | $2.80M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.40M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $1.30M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $1.30M 10-K · filed 2021-03-25 | |||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-13 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $0.00 derived: sum of 2 quarters · filed 2020-03-12 | $200.00K derived: sum of 3 quarters · filed 2020-03-12 | $300.00K 10-K · filed 2020-03-12 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $200.00K derived: sum of 2 quarters · filed 2018-11-07 | $300.00K 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $200.00K 10-Q · filed 2018-08-08 | $300.00K 10-Q · filed 2018-08-08 | ||
| 2018-03-31 | $100.00K 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $200.00K 10-K · filed 2018-03-12 | |||
| 2016-12-31 | $277.00K 10-K · filed 2017-03-09 | |||
| 2015-12-31 | $2.33K 10-K · filed 2016-03-14 | |||
| 2014-12-31 | $141.00 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $141.00 10-Q · filed 2014-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |